Bairma B. Dambaeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bairma B. Dambaeva has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Onuchina
Irkutsk State Medical Academy of Postgraduate Education – branch of Russian Medical Academy of Continuous Professional Education
4 shared publications Б. Б. Дамбаева
Иркутская государственная медицинская академия последипломного образования – филиал Российской медицинской академии непрерывного профессионального образования
2 shared publicationsЕ. В. Онучина
Иркутская государственная медицинская академия последипломного образования – филиал Российской медицинской академии непрерывного профессионального образования
2 shared publicationsA. G. Glazunova
Irkutsk Medical and Sanitary Unit No. 2
1 shared publicationA. K. Mikhaylova
Expert Clinic
1 shared publication- Alexander Gornov
Matrosov Institute for System Dynamics and Control Theory of SB RAS
1 shared publication
Latest Publications
- Open Access
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 29-39
Clinical and functional dynamics of parameters in patients with gastroesophageal reflux disease – functional dyspepsia overlap during acotiamide and rabeprazole combination therapy in the prospective observational OVERLAP study
Introduction. Combination of proton pump inhibitor and prokinetic has been found to be the most promising strategy for managing the monopathology of both gastroesophageal reflux disease (GERD) and functional dyspepsia (FD). However, in literature there are only single studies devoted to the effect of the rabeprazole + acotiamide combination on the GERD – FD overlap. Aim. To evaluate the efficacy of 4-week therapy with a combination of rabeprazole 20 mg/day + acotiamide 100 mg three times a day in patients with GERD – FD overlap. Materials and methods. We conducted a single-site, prospective, open-label, observational, non-comparative study OVERLAP. The treatment results were assessed on the basis of an analysis of changes in the GERD and FD symptoms frequency, severity (Likert scale), and mFSSG scores; QoL testing using the SF-8 and SF-NDI questionnaires; comparison of baseline and final 24-h pH-impedance, EGDS measurements; assessment of patient and physician satisfaction with treatment; and treatment tolerability. Results. GERD-associated symptoms were relieved in 96.7% of patients, while FD-associated complaints were relieved in 93.3% of patients. The treatment significantly reduced the AET and DeMeester scores. Separate analysis of reflux phenotype dynamics revealed a 2.2-fold decrease in acid reflux, a 1.7-fold decrease in non-acid reflux, a 1.9-fold decrease in liquid reflux, and a 1.6-fold decrease in mixed reflux. The patients demonstrated essential enhancement of protective mechanisms: a significant increase in the post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance at Z1 with a decrease in the bolus exposure time. The pronounced positive changes in all quality-of-life parameters were reported. Conclusion. Rabeprazole Razo® and acotiamide Dyspevict® combination therapy led to regression of clinical manifestations and improved the quality of life in patients with GERD and FD. The suppression of gastric hypersecretion and elimination of motorevacuation dysfunction formed the pathogenic basis for positive clinical response. The combination is safe, well-tolerated, and can be recommended for common use in patients with GERD and FD.
- 24 October 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 15,p. 29-39
Open AccessClinical and functional dynamics of parameters in patients with gastroesophageal reflux disease – functional dyspepsia overlap during acotiamide and rabeprazole combination therapy in the prospective observational OVERLAP study
Introduction. Combination of proton pump inhibitor and prokinetic has been found to be the most promising strategy for managing the monopathology of both gastroesophageal reflux disease (GERD) and functional dyspepsia (FD). However, in literature there are only single studies devoted to the effect of the rabeprazole + acotiamide combination on the GERD – FD overlap. Aim. To evaluate the efficacy of 4-week therapy with a combination of rabeprazole 20 mg/day + acotiamide 100 mg three times a day in patients with GERD – FD overlap. Materials and methods. We conducted a single-site, prospective, open-label, observational, non-comparative study OVERLAP. The treatment results were assessed on the basis of an analysis of changes in the GERD and FD symptoms frequency, severity (Likert scale), and mFSSG scores; QoL testing using the SF-8 and SF-NDI questionnaires; comparison of baseline and final 24-h pH-impedance, EGDS measurements; assessment of patient and physician satisfaction with treatment; and treatment tolerability. Results. GERD-associated symptoms were relieved in 96.7% of patients, while FD-associated complaints were relieved in 93.3% of patients. The treatment significantly reduced the AET and DeMeester scores. Separate analysis of reflux phenotype dynamics revealed a 2.2-fold decrease in acid reflux, a 1.7-fold decrease in non-acid reflux, a 1.9-fold decrease in liquid reflux, and a 1.6-fold decrease in mixed reflux. The patients demonstrated essential enhancement of protective mechanisms: a significant increase in the post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance at Z1 with a decrease in the bolus exposure time. The pronounced positive changes in all quality-of-life parameters were reported. Conclusion. Rabeprazole Razo® and acotiamide Dyspevict® combination therapy led to regression of clinical manifestations and improved the quality of life in patients with GERD and FD. The suppression of gastric hypersecretion and elimination of motorevacuation dysfunction formed the pathogenic basis for positive clinical response. The combination is safe, well-tolerated, and can be recommended for common use in patients with GERD and FD.
- Open Access
- 30 July 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 2,p. 26-38
CLINICAL AND FUNCTIONAL FEATURES OF COMORBIDITY OF GASTROESOPHAGEAL REFLUX DISEASE AND OBSTRUCTIVE SLEEP APNEA SYNDROME
Objective. To evaluate the clinical and functional features of GERD and OSAS comorbidity. Materials and methods. The study included 144 patients with verified GERD. All participants underwent medical history taking, anthropometry, questionnaire surveys (GERDQ, Berlin Questionnaire for apnea), esophagogastroduodenoscopy and 24-hour esophageal pH-impedance monitoring. Patients identified as high risk for OSAS by the questionnaire underwent cardiorespiratory monitoring to confirm the diagnosis. Using multivariate discriminant analysis, we identified a set of features and developed a mathematical model to determine the probability of reflux-associated sleep apnea in patients with GERD. To confirm the results of discriminant analysis and adjust for initial differences in anthropometric parameters, multivariate logistic regression analysis was additionally applied. Results. Patients with GERD and OSAS comorbidity had significantly higher BMI, waist circumference, and a higher prevalence of otolaryngological pathology. According to pH-impedance monitoring, this group showed statistically significant differences: higher total AET, a higher number of proximal mixed weakly acidic reflux episodes, longer bolus exposure time in the supine position, as well as lower index PSPW and MNBI in the proximal esophagus. Multivariate discriminant analysis identified 8 key predictive features and developed two functions (F₁ > F₂). The method demonstrated a sensitivity of 98,43% and specificity of 97,44%. Multivariate logistic regression analysis adjusted for BMI and waist circumference confirmed the preservation of significant differences in key reflux parameters between the groups. Conclusion. The obtained data confirm the potential significance of impaired volume and chemical esophageal clearance (decreased PSPW index, increased bolus exposure time), disrupted epithelial barrier integrity in the proximal esophagus (decreased proximal MNBI), and the predominance of proximal weakly acidic nocturnal reflux in GERD and OSAS comorbidity.
- 30 July 2026
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 2,p. 26-38
Open AccessCLINICAL AND FUNCTIONAL FEATURES OF COMORBIDITY OF GASTROESOPHAGEAL REFLUX DISEASE AND OBSTRUCTIVE SLEEP APNEA SYNDROME
Objective. To evaluate the clinical and functional features of GERD and OSAS comorbidity. Materials and methods. The study included 144 patients with verified GERD. All participants underwent medical history taking, anthropometry, questionnaire surveys (GERDQ, Berlin Questionnaire for apnea), esophagogastroduodenoscopy and 24-hour esophageal pH-impedance monitoring. Patients identified as high risk for OSAS by the questionnaire underwent cardiorespiratory monitoring to confirm the diagnosis. Using multivariate discriminant analysis, we identified a set of features and developed a mathematical model to determine the probability of reflux-associated sleep apnea in patients with GERD. To confirm the results of discriminant analysis and adjust for initial differences in anthropometric parameters, multivariate logistic regression analysis was additionally applied. Results. Patients with GERD and OSAS comorbidity had significantly higher BMI, waist circumference, and a higher prevalence of otolaryngological pathology. According to pH-impedance monitoring, this group showed statistically significant differences: higher total AET, a higher number of proximal mixed weakly acidic reflux episodes, longer bolus exposure time in the supine position, as well as lower index PSPW and MNBI in the proximal esophagus. Multivariate discriminant analysis identified 8 key predictive features and developed two functions (F₁ > F₂). The method demonstrated a sensitivity of 98,43% and specificity of 97,44%. Multivariate logistic regression analysis adjusted for BMI and waist circumference confirmed the preservation of significant differences in key reflux parameters between the groups. Conclusion. The obtained data confirm the potential significance of impaired volume and chemical esophageal clearance (decreased PSPW index, increased bolus exposure time), disrupted epithelial barrier integrity in the proximal esophagus (decreased proximal MNBI), and the predominance of proximal weakly acidic nocturnal reflux in GERD and OSAS comorbidity.
- Open Access
- 8 May 2025
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 1,p. 33-45
The parameters of daily pH-impedancemetry in patients with comorbidity of gastroesophageal reflux disease and obstructive sleep apnea syndrome
Objective. To evaluate the parameters of daily pH-impedancemetry of the esophagus monitoring in case of comorbidity of gastroesophageal reflux disease (GERD) and obstructive sleep apnea syndrome (OSAS) in comparison with monopathology of GERD.Materials and methods. A cross-sectional study was conducted at the therapeutic department of the private healthcare institution Hospital “RZD medicine” in Irkutsk of two groups of patients: with GERD and GERD in combination with OSAS. GERD was verified in accordance with the clinical recommendations of the Russian Gastroenterological Association (2020), Lyon Consensus 2.0 (2024). The diagnosis of OSAS was established in accordance with the criteria of the Eurasian Association of Cardiologists and the Russian Society of Sleep Medicine (2024). Statistical processing of the obtained data was performed using Statistica 10.0 (StatSoft, USA).Results. The GERD group included 14 patients (46,7%), the GERD and OSAS group included 16 patients, the groups were comparable by age and gender. In the GERD and OSAS group, compared with the GERD group, the following were higher: total AET (p = 0,04), in the supine position during sleep (p = 0,002); Demeester index (p = 0,013); duration of refluxes (p = 0,007); total number of refluxes (p = 0,06); in the supine position during sleep, the total number of refluxes (p = 0,002) and the number of refluxes reaching 19 cm above the LES (p = 0,051). In the GERD and OSAS group, compared with the GERD group, MNBI at the Z1 level (p = 0,003) and the PSPW index (p = 0,05) were lower.Conclusion. In case of comorbidity of GERD and OSAS, in comparison with GERD, more pronounced low and high acid reflux, especially in the supine position, impaired esophageal clearance with a decrease in the MNBI and PSPW index were found.
- 8 May 2025
- Published by Chita State Medical Academy in Transbaikalian Medical Bulletin
- No. 1,p. 33-45
Open AccessThe parameters of daily pH-impedancemetry in patients with comorbidity of gastroesophageal reflux disease and obstructive sleep apnea syndrome
Objective. To evaluate the parameters of daily pH-impedancemetry of the esophagus monitoring in case of comorbidity of gastroesophageal reflux disease (GERD) and obstructive sleep apnea syndrome (OSAS) in comparison with monopathology of GERD.Materials and methods. A cross-sectional study was conducted at the therapeutic department of the private healthcare institution Hospital “RZD medicine” in Irkutsk of two groups of patients: with GERD and GERD in combination with OSAS. GERD was verified in accordance with the clinical recommendations of the Russian Gastroenterological Association (2020), Lyon Consensus 2.0 (2024). The diagnosis of OSAS was established in accordance with the criteria of the Eurasian Association of Cardiologists and the Russian Society of Sleep Medicine (2024). Statistical processing of the obtained data was performed using Statistica 10.0 (StatSoft, USA).Results. The GERD group included 14 patients (46,7%), the GERD and OSAS group included 16 patients, the groups were comparable by age and gender. In the GERD and OSAS group, compared with the GERD group, the following were higher: total AET (p = 0,04), in the supine position during sleep (p = 0,002); Demeester index (p = 0,013); duration of refluxes (p = 0,007); total number of refluxes (p = 0,06); in the supine position during sleep, the total number of refluxes (p = 0,002) and the number of refluxes reaching 19 cm above the LES (p = 0,051). In the GERD and OSAS group, compared with the GERD group, MNBI at the Z1 level (p = 0,003) and the PSPW index (p = 0,05) were lower.Conclusion. In case of comorbidity of GERD and OSAS, in comparison with GERD, more pronounced low and high acid reflux, especially in the supine position, impaired esophageal clearance with a decrease in the MNBI and PSPW index were found.
- Open Access
- 27 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (12) , 1198-1205
Non-alcoholic fatty liver disease and cognitive impairment
Aim. To evaluate the efficacy of oral administration of the original ademetionine (Geptral) at a dose of 1500 mg/s in patients with NAFLD at the steatosis stage and cognitive impairment within the framework of a prospective observational open non-comparative study in real clinical practice against the background of achieved lifestyle modification. Materials and methods. Thirty patients with NAFLD and cognitive impairment were examined using routine methods examination. NAFLD was diagnosed in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation. All patients met the criteria for MAFLD. Cognitive functions were assessed using the Montreal Cognitive Assessment Scale. After selection, patients were recommended dietary and physical activity modification in combination with oral administration of the original ademetionine at a dose of 1500 mg/day. The duration of the study was 6 months. Results. Oral administration of the original ademetionine for 6 months against the background of lifestyle modification improved cognitive functions with an increase in the Montreal Cognitive Assessment Scale score from 19.1 (16.3–20.1) to 27.6 (25.1–29.0; p=0.001). In addition, the study found a decrease in the severity of steatosis according to the FLI index and quantitative ultrasound. Additionally, a decrease in the Fatigue Assessment Scale (FAS) scores from 34 [25–39] to 19 [16–27]; p=0.000002, and 10-year fatal and non-fatal cardiovascular risk according to the SCORE2 scale from 34 [15–44] to 9 [7–13]; p=0.000002, was revealed. Conclusion. The original ademetionine as a multitarget drug for NAFLD may be useful in terms of improving cognitive functions, increasing adherence to lifestyle modification, and improving its quality and duration.
- 27 December 2024
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 96 (12) , 1198-1205
Open AccessNon-alcoholic fatty liver disease and cognitive impairment
Aim. To evaluate the efficacy of oral administration of the original ademetionine (Geptral) at a dose of 1500 mg/s in patients with NAFLD at the steatosis stage and cognitive impairment within the framework of a prospective observational open non-comparative study in real clinical practice against the background of achieved lifestyle modification. Materials and methods. Thirty patients with NAFLD and cognitive impairment were examined using routine methods examination. NAFLD was diagnosed in accordance with the clinical guidelines of the Ministry of Health of the Russian Federation. All patients met the criteria for MAFLD. Cognitive functions were assessed using the Montreal Cognitive Assessment Scale. After selection, patients were recommended dietary and physical activity modification in combination with oral administration of the original ademetionine at a dose of 1500 mg/day. The duration of the study was 6 months. Results. Oral administration of the original ademetionine for 6 months against the background of lifestyle modification improved cognitive functions with an increase in the Montreal Cognitive Assessment Scale score from 19.1 (16.3–20.1) to 27.6 (25.1–29.0; p=0.001). In addition, the study found a decrease in the severity of steatosis according to the FLI index and quantitative ultrasound. Additionally, a decrease in the Fatigue Assessment Scale (FAS) scores from 34 [25–39] to 19 [16–27]; p=0.000002, and 10-year fatal and non-fatal cardiovascular risk according to the SCORE2 scale from 34 [15–44] to 9 [7–13]; p=0.000002, was revealed. Conclusion. The original ademetionine as a multitarget drug for NAFLD may be useful in terms of improving cognitive functions, increasing adherence to lifestyle modification, and improving its quality and duration.